Azure Biotech Announces Educational Initiative to Create Awareness of Unmet Women’s Menopausal Medical Issue
30 août 2023 12h55 HE
|
Azure Biotech
RIVER VALE, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Azure Biotech, Inc., a privately held women’s health company that is developing novel formulations of lasofoxifene for vulvovaginal atrophy (VVA),...
Dyspareunia Treatment Market Poised for 4.1% CAGR Surge, Touches USD 1.02 Billion by 2031 | Transparency Market Research
29 mai 2023 12h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, May 29, 2023 (GLOBE NEWSWIRE) -- The dyspareunia treatment market generated US$ 689 million in 2022. Globally, the market is expected to reach US$ 1.02 billion...
Solas BioVentures Co-Founder David Adair, M.D. Joins Mayfield Pharmaceuticals Board of Directors
23 oct. 2019 07h30 HE
|
Harrow Health, Inc.
BOSTON, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced David Adair, M.D. will join the...
Mayfield Pharmaceuticals to Present at the SVB Leerink New Treatments Focused on Women’s Health Conference on October 10, 2019
08 oct. 2019 07h35 HE
|
Harrow Health, Inc.
BOSTON, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced its Chief Executive Officer, Melissa...
Harrow Health Announces Launch of Mayfield Pharmaceuticals
31 juil. 2019 07h30 HE
|
Harrow Health, Inc.
NASHVILLE, Tenn., July 31, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), today announced it has filed a Form 8-K with the Securities and Exchange Commission containing a corporate...
Harrow Health Subsidiary, Mayfield Pharmaceuticals, Inc., Acquires Patented Dyspareunia Drug Candidate and Other Intellectual Property
07 févr. 2019 07h00 HE
|
Harrow Health, Inc.
SAN DIEGO, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), today announced that its subsidiary, Mayfield Pharmaceuticals, Inc., has acquired drug formulation assets and...